Bluestein R H & Co. lowered its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 68.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,465 shares of the medical research company’s stock after selling 11,700 shares during the period. Bluestein R H & Co.’s holdings in Edwards Lifesciences Corporation were worth $646,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Edwards Lifesciences Corporation by 2.0% in the second quarter. Vanguard Group Inc. now owns 20,748,569 shares of the medical research company’s stock valued at $2,453,311,000 after purchasing an additional 406,901 shares during the period. BlackRock Inc. grew its position in shares of Edwards Lifesciences Corporation by 0.8% in the second quarter. BlackRock Inc. now owns 14,109,514 shares of the medical research company’s stock valued at $1,668,309,000 after purchasing an additional 105,819 shares during the period. State Street Corp grew its position in shares of Edwards Lifesciences Corporation by 1.7% in the first quarter. State Street Corp now owns 9,388,994 shares of the medical research company’s stock valued at $883,219,000 after purchasing an additional 157,844 shares during the period. Alliancebernstein L.P. grew its position in shares of Edwards Lifesciences Corporation by 29.8% in the first quarter. Alliancebernstein L.P. now owns 6,366,425 shares of the medical research company’s stock valued at $598,890,000 after purchasing an additional 1,459,921 shares during the period. Finally, Bank of New York Mellon Corp grew its position in shares of Edwards Lifesciences Corporation by 161.7% in the second quarter. Bank of New York Mellon Corp now owns 5,304,536 shares of the medical research company’s stock valued at $627,207,000 after purchasing an additional 3,277,726 shares during the period. 82.08% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Edwards Lifesciences Corporation (EW) Stake Lowered by Bluestein R H & Co.” was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.dailypolitical.com/2017/09/23/edwards-lifesciences-corporation-ew-stake-lowered-by-bluestein-r-h-co.html.

In related news, VP Larry L. Wood sold 18,960 shares of Edwards Lifesciences Corporation stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $112.58, for a total transaction of $2,134,516.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Catherine M. Szyman sold 4,681 shares of Edwards Lifesciences Corporation stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $115.78, for a total value of $541,966.18. The disclosure for this sale can be found here. Over the last three months, insiders have sold 182,501 shares of company stock worth $20,847,236. 2.13% of the stock is owned by company insiders.

A number of equities research analysts have recently commented on EW shares. Jefferies Group LLC set a $115.00 price objective on Edwards Lifesciences Corporation and gave the company a “buy” rating in a research report on Saturday, May 27th. Bank of America Corporation lifted their price objective on Edwards Lifesciences Corporation from $120.00 to $140.00 and gave the company a “buy” rating in a research report on Tuesday, May 30th. Royal Bank Of Canada reissued a “buy” rating on shares of Edwards Lifesciences Corporation in a research report on Tuesday, May 30th. Zacks Investment Research downgraded Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, May 31st. Finally, BidaskClub downgraded Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. Six equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $120.75.

Shares of Edwards Lifesciences Corporation (NYSE:EW) traded up 0.28% during mid-day trading on Friday, reaching $110.64. The company’s stock had a trading volume of 970,645 shares. The stock has a market capitalization of $23.36 billion, a P/E ratio of 33.56 and a beta of 0.64. Edwards Lifesciences Corporation has a 12 month low of $81.12 and a 12 month high of $121.75. The company has a 50 day moving average price of $113.80 and a 200 day moving average price of $109.37.

Edwards Lifesciences Corporation (NYSE:EW) last released its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The business had revenue of $842.00 million for the quarter, compared to the consensus estimate of $839.16 million. During the same period last year, the business earned $0.76 earnings per share. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current fiscal year.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.